Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arvaya Healthcare's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 21.99.
Arvaya Healthcare's Days Inventory for the
three
months ended in Mar. 2026 was 38.85.
Arvaya Healthcare's Days Payable for the
three
months ended in Mar. 2026 was 233.68.
Therefore, Arvaya Healthcare's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was -172.84.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Arvaya Healthcare Cash Conversion Cycle Related Terms
Arvaya Healthcare Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Arvaya Healthcare's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524723 vs MCK, CAH, COR: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Arvaya Healthcare's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arvaya Healthcare Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arvaya Healthcare's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Arvaya Healthcare's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Arvaya Healthcare's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of -172.84 mean?
Arvaya Healthcare (BOM:524723) has a Cash Conversion Cycle of -172.84 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Arvaya Healthcare and its competitors.
Is Arvaya Healthcare's Cash Conversion Cycle too high?
Arvaya Healthcare's current Cash Conversion Cycle is -172.84. Overall, Arvaya Healthcare has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arvaya Healthcare's Cash Conversion Cycle compare to MCK and CAH?
Arvaya Healthcare's Cash Conversion Cycle of -172.84 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 52.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 52.15, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Arvaya Healthcare and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 52.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arvaya Healthcare's current Cash Conversion Cycle is -172.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvaya Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Arvaya Healthcare (BOM:524723) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹49.48, compared to a current price of ₹114.71 — trading 131.8% above its estimated fair value. The current Cash Conversion Cycle is -172.84. Arvaya Healthcare's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Arvaya Healthcare (BOM:524723), the current Cash Conversion Cycle is -172.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arvaya Healthcare (BOM:524723) Overvalued in 2026?
Based on GuruFocus' analysis, Arvaya Healthcare stock appears to be overvalued.
The current stock price of ₹114.71 is trading 131.8% above its estimated GF Value™ of ₹49.48.
GuruFocus considers Arvaya Healthcare to be Significantly Overvalued.
Key valuation signals for BOM:524723:
Cash Conversion Cycle: -172.84
GF Value™: ₹49.48 vs. price of ₹114.71 (131.8% above fair value)
No single metric tells the full story. See the BOM:524723 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arvaya Healthcare Ltd is focused on developing an integrated healthcare platform in India that combines hospital services, diagnostics, wellness services, and digital health management solutions. Its operations include multi-specialty hospitals, a digital health platform for appointment booking and health record management, diagnostic services including laboratory testing and home sample collection, and wellness facilities offering preventive and recovery-focused programs.
36GF Score
Get the complete analysis for BOM:524723
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524723 has been successfully added to your 
